Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Swedish Orphan Biovitrum AB (Publ)
Femme et Homme Max 99 ans
Swedish Orphan Biovitrum AB (Publ)
MAJ Il y a 5 ans
An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed with hereditary tyrosinemia type 1
To evaluate the steady-state exposure to nitisinone during once and twice daily dosing of Orfadin
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Swedish Orphan Biovitrum AB (Publ)
MAJ Il y a 5 ans
A phase 3 clinical study investigating the effects of rhBSSL (an enzyme to help digestion of fat) added to pasteurized breast milk or formula in babies born prematurely
The primary objective of this study is to demonstrate that rhBSSL improves growth in preterm infants as compared with placebo when administered in infant formula or PBM.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Swedish Orphan Biovitrum AB (Publ)
MAJ Il y a 5 ans
To determine a safe and tolerable dose of palifermin in pediatric subjects of different age groups when administered once daily for 3 consecutive days before and 3 consecutive days after a myeloablative chemo-radiotherapy conditioning regimen with allogeneic hematopoietic stem cell transplant (HSCT)
To determine a safe and tolerable dose of palifermin in pediatric subjects of different age groups when administered once daily for 3 consecutive days before and 3 consecutive days after a myeloablati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Swedish Orphan Biovitrum AB (Publ)
MAJ Il y a 5 ans
A study to evaluate the effects of palifermin in reducing mouth ulceration in subjects with locally advanced head and neck cancer
To evaluate the pharmacokinetic profile and biological activity on buccal mucosae of palifermin administered at the dose of 120 μg/kg IV in a cohort of at least 16 (3 palifermin : 1 placebo) locally a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations